Drug Profile
MK 7145
Alternative Names: MK-7145Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 15 Feb 2015 Discontinued - Phase-I for Hypertension in Australia and New Zealand (PO)
- 15 Feb 2015 Merck terminates a phase I trial in Hypertension in Australia and New Zealand (PO) (NCT01558674)
- 31 Oct 2014 Discontinued - Phase-I for Hypertension in South Africa (PO)